Last Call for canSERV Third Open Call Funding
One document
more
Stories about Biomarker
- Language:
- Media:
- Period:
- Period:Total
Launch of canSERV Call for Service Provision – "Training the Next Generation of Cancer Researchers"
One documentmorecanSERV relaunches Open Call for Service Provision
One documentmorecanSERV invites applications for "Revolutionising Cancer Patient Care"
One documentmore- 3
canSERV invites applications for "Revolutionising Cancer Patient Care"
One documentmore LAST CHANCE: canSERV Second Open Call for Cancer Research Service Provision
One documentmore- 3
canSERV Initiative: EU Consortium Launches Groundbreaking Call to Accelerate Cancer Research
One documentmore New Source of Stem Cells in Injury-Affected Brains of Patients
more- 3
EU Provides 1 Mio. to Researchers to Advance Personalised Oncology
One documentmore canSERV Releases Open Call for Transnational Service Provision
One documentmoreFirst Integrated Single-Cell Atlas of the Human Lung
Can a human organ be mapped on a single-cell level to learn about the functionality of each individual cell? And can we learn how different these cells are from person to person? Helmholtz Munich researchers and their collaborators have taken up this challenge and developed the Human Lung Cell Atlas using artificial intelligence (AI)-based techniques. This atlas elucidates the diversity of single lung cell types and ...
moreArtificial intelligence in intensive care units: University Hospital Freiburg relies on x-cardiac technology in clinical routine
Berlin (ots) - Berlin-based x-cardiac GmbH is pleased to announce that Freiburg University Hospital has become the second pilot customer for its AI-based software "x-c-bleeding" for predicting severe bleeding complications after cardiac surgery. With the implementation of "x-c-bleeding", the University Hospital ...
moreGenialis Raises $13M to Build Clinical Biomarkers that Predict Patient Response
BOSTON, LAUSANNE & LJUBLJANA, Slovenia (ots) - Debiopharm Innovatoin Fund & Taiwania Capital co-lead financing round for Genialis to propel drug development, diagnostics and treatment planning through AI/ML-enabled platform with a biology-first approach Genialis, a computational precision medicine company unraveling complex biology to find new ways to address disease, ...
moreDEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCi™ STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
Lausanne, Switzerland (ots/PRNewswire) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and ...
moreDEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCiTM STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
Lausanne, Switzerland (ots) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and treatment of ...
more- 2
Free Access to Cancer Research Services - canSERV 1st Call for Proposals
more Free Access to Cancer Research Services - canSERV 1st Call for Proposals
One documentmoreTechnische Universität München
New center for digital medicine and health
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/press-releases/details/37491 Images: https://mediatum.ub.tum.de/1663381 NEWS RELEASE Interdisciplinary research for the digital medicine of the future Federal and state governments approve funding for digital medicine and health center ...
moreTechnische Universität München
Same symptom – different cause? Algorithms help to distinguish diseases at the molecular level
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 8161 5403 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/press-releases/details/37411 High resolution images: https://mediatum.ub.tum.de/1659820 NEWS RELEASE Same symptom – different cause? Algorithms help to distinguish diseases at the ...
moreUniversity of Chicago Clinical Trial Utilizes Sysmex Inostics Highly Effective HPV-SEQ Test to Measure HPV-DNA from Blood of Neck and Throat Cancer Patients
Baltimore, MD (ots) - Sysmex Inostics, a global leader in the liquid biopsy revolution for oncology, announces the use of their HPV-SEQ test in the prospective University of Chicago clinical trial,1 “Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer.” “The ability to reliably detect HPV-DNA ...
moreNew Ultra-Sensitive Leukemia Blood Test Delivered by Sysmex Inostics
moreTechnische Universität München
Taking aim at skin bacteria
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22562 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36873/ Video: https://youtu.be/qMsYJGqJLlQ NEWS RELEASE Taking aim at skin bacteria Enzyme treatment of skin samples improves microbiome analysis Healthy skin has a bacterial shield to protect against germs: the microbiome. This complex assembly of microorganisms ...
more- 3
World Cancer Day: Start-ups at the IZB develop innovative cancer drugs and diagnostic tools
One documentmore COVID-19: Use rapid tests to identify important biomarkers and predict the course of the disease
Moers (ots) - Whether it’s a lung embolism or a heart attack – an infection with coronavirus can have life-threatening consequences. But how badly will different patients be affected by COVID-19? This can be determined by certain biomarkers. nal von minden GmbH’s biomarker rapid tests from Germany deliver reliable results in just 15 minutes. An infection with ...
moreTechnische Universität München
Fighting corona with machine learning
Corporate Communications Center phone: +49 8161 5403 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36254/ NEWS RELEASE The Bavarian Research Foundation is funding five TUM-research projects on Covid-19 Fighting corona with machine learning The Technical University of Munich (TUM) is starting five new research projects that focus on the ...
moreSysmex Inostics' Liquid Biopsy Testing Benefits Metastatic Pancreatic Cancer Patient Management
Baltimore, MD (ots) - Sysmex Inostics, Inc., a global leader and pioneer in blood-based circulating cell-free tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study investigating the utility of cfDNA-based markers using the highly sensitive OncoBEAM RAS assay, an enhanced ...
moreSysmex-Inostics Colorectal Cancer Blood-Based OncoBEAMTM RAS CE-IVD Test Shows Concordance with Standard of Care Tissue-Based RAS Testing
Baltimore, Maryland (ots) - Sysmex-Inostics, Inc., a global leader and pioneer in blood-based circulating tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study evaluating the performance of plasma RAS mutation testing with OncoBEAM RAS CRC as compared to standard of care ...
moreTechnische Universität München
Gut bacteria improve type 2 diabetes risk prediction
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 8161 5403 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36118/ Images for journalists: https://mediatum.ub.tum.de/1552269 NEWS RELEASE Large-scale study with more than 4000 participants at ZIEL - Institute for Food & Health Gut bacteria improve type 2 diabetes risk ...
moreNasal biomarkers predict severity of pollen-specific allergy symptoms
Nasal biomarkers predict severity of pollen-specific allergy symptoms It is not only people with allergies, but also a subgroup of people without one that suffer in spring and have nasal problems from contact with pollen. A new study shows that biomarkers in the nose can predict ...
moreSysmex Inostics' updated SafeSEQ Breast Cancer Panel advances novel clinical uses of ctDNA through quantitative testing
Baltimore, Maryland (ots) - Building on the ultra-high sensitivity SafeSEQ Breast Cancer Panel circulating tumor DNA (ctDNA) test launched at the American Association of Cancer Research 2019 annual meeting, Sysmex Inostics has updated the test to provide additional key information for investigation of the validity ...
more
12Next